N
CCCC icon

Nuveen’s C4 Therapeutics CCCC Stock Holding History

Nuveen’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-192,424
Closed -$308K – 3292
2025
Q1 		$308K Hold
192,424
– – ﹤0.01% 3038
2024
Q4 		$693K Buy
192,424
+11,571
+6% +$57.5K ﹤0.01% 2863
2024
Q3 		$1.03M Sell
180,853
-250,160
-58% -$1.51M ﹤0.01% 2748
2024
Q2 		$1.99M Buy
+431,013
New +$2.57M ﹤0.01% 2400
2023
Q2 		– Sell
-356,609
Closed -$1.12M – 3221
2023
Q1 		$1.12M Sell
356,609
-20,915
-6% -$123K ﹤0.01% 2571
2022
Q4 		$2.23M Sell
377,524
-24,360
-6% -$202K ﹤0.01% 2342
2022
Q3 		$3.52M Sell
401,884
-6,175
-2% -$64.1K ﹤0.01% 2101
2022
Q2 		$3.08M Sell
408,059
-12,395
-3% -$109K ﹤0.01% 2213
2022
Q1 		$9.77M Buy
420,454
+157,052
+60% +$3.81M ﹤0.01% 1654
2021
Q4 		$7.47M Sell
263,402
-43,934
-14% -$1.74M ﹤0.01% 1858
2021
Q3 		$15.4M Buy
307,336
+106,944
+53% +$4.58M ﹤0.01% 1462
2021
Q2 		$7.58M Buy
200,392
+97,078
+94% +$3.48M ﹤0.01% 2021
2021
Q1 		$3.82M Buy
103,314
+78,690
+320% +$3.13M ﹤0.01% 2300
2020
Q4 		$816K Buy
+24,624
New +$714K ﹤0.01% 2879

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's CCCC Position: Q2 2025 in Review

Nuveen sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 192,424 shares — an estimated $308K sold.

Nuveen first reported a position in CCCC in Q4 2020 and held it in 14 quarters. The position peaked at $15.4M in Q3 2021. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • Nuveen reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 192,424 C4 Therapeutics shares in Q2 2025, an estimated $308K.
  • Nuveen first reported a position in C4 Therapeutics in Q4 2020 and held it in 14 quarters.
  • Nuveen's C4 Therapeutics position peaked at $15.4M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.